Review
Falling into TRAPS – receptor misfolding in the TNF receptor 1-associated periodic fever syndrome
Fiona C Kimberley1, Adrian A Lobito2, Richard M Siegel3 and Gavin R Screaton4

1Laboratory for Experimental Oncology and Radiobiology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
2Genetech, 1 DNA Way, MS 63, South San Francisco, CA 94080, USA
3Immunoregulation Unit, Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD 20892, USA
4Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK

Abstract
TNF receptor-associated periodic syndrome (TRAPS) is a dominantly inherited disease caused by missense mutations in the TNF receptor 1 (TNFR1) gene. Patients suffer from periodic bouts of severe abdominal pain, localised inflammation, migratory rashes, and fever. More than 40 individual mutations have been identified, all of which occur in the extracellular domain of TNFR1. In the present review we discuss new findings describing aberrant trafficking and function of TNFR1 harbouring TRAPS mutations, challenging the hypothesis that TRAPS pathology is driven by defective receptor shedding, and we suggest that TNFR1 might acquire novel functions in the endoplasmic reticulum, distinct from its role as a cell surface receptor. We also describe the clinical manifestations of TRAPS, current treatment regimens, and the widening array of patient mutations.

Introduction
The periodic fevers are a group of disorders characterised by unprovoked attacks of fever and localised inflammation that can affect multiple organ systems [1]. There are several periodic fever syndromes that are inherited in a recessive manner, such as familial Mediterranean fever (FMF) caused by mutations in the gene encoding the neutrophil-specific protein Pyrin [2]. Most evidence currently suggests that pyrin negatively regulates the production of IL-1β – a major proinflammatory cytokine of the innate immune response [3]. IL-1β is generated from its proform via cleavage by caspase-1, which occurs in a specialised IL-1 activating protein complex termed the inflammasome [4-6]. FMF-associated mutations in pyrin are thought to exert less inhibition of IL-1β processing [7]. Another such recessive disease is hyperimmunoglobulin-D with periodic fever syndrome, which arises due to mutations in mevalonate kinase – a key enzyme in cholesterol biosynthesis and the synthesis of nonsterol isoprenoid molecules [8,9]. The exact molecular basis for the disease resulting from these mutations, however, remains unclear.

The molecular basis of two groups of dominant periodic fever syndromes has been identified. Dominant mutations in the CIAS1 gene are associated with a heterogeneous group of inflammatory conditions encompassing Muckle–Wells syndrome, familial cold autoinflammatory syndrome, and the neonatal onset multisystem inflammatory disease [10]. CIAS1 is one of the intracellular sensors that activate the inflammasome, and it is thought that CIAS1 mutations associated with these diseases might lead to its constitutive activation. Through studies of cohorts of patients with dominantly inherited familial periodic fevers, formerly classified as dominant periodic syndrome and familial Hibernian fever, mutations in the TNFR1 gene on chromosome 12p13 were identified. These patients were therefore classified as having TRAPS [11-13]. TNFR1 is the archetypal proinflammatory receptor and a member of the TNF receptor superfamily – a
large group of proteins with homology in their extracellular domains, which are involved in a variety of processes including inflammation, T-cell activation, B-cell homeostasis, and osteoclast function.

The mean age of onset for TRAPS is 3 years, but diagnoses have been made at ages ranging from 2 weeks to 53 years. Unlike FMF, in which attacks are predictably less than 5 days in duration, febrile attacks in TRAPS can last from a few days to months, with an average duration of 21 days. There is no fixed periodicity between attacks; they can occur as frequently as every 5–6 weeks, or patients can be symptom-free for months to years. Attacks are usually unprovoked, but they have been reported to be triggered or aggravated by several factors, such as local injury, minor infection, stress, exercise, and hormonal changes – attacks are often relieved during pregnancy [14,15]. The most common symptoms associated with an attack are fever, a migrating radial rash on the limbs, and extreme abdominal and muscle pain, but symptoms can also include conjunctivitis, headaches, chest pain, myalgia, arthralgia, and less commonly arthritis and other inflammatory manifestations including fasciitis, myocarditis, sacroiliitis, pharyngitis, and stomatitis [16-19]. The most serious complication associated with TRAPS is systemic amyloidosis – extracellular deposits of an insoluble cleavage product of the acute-phase reactant protein serum amyloid A. Many patients with renal amyloidosis develop nephrotic syndrome and progress to renal failure.

Laboratory findings in TRAPS are in accordance with a typical inflammatory episode: high levels of C-reactive protein, neutrophilia, moderate complement activation, raised mean erythrocyte sedimentation rate, and, in some cases, marginally raised IgA and IgD levels [16,17,20-22]. Importantly, acute phase proteins can also be elevated between attacks, suggesting that subclinical inflammation may be more chronic [23]. Cytokine profiling of a small group of TRAPS patients revealed that IL-6 was relatively more elevated than TNFα, when compared with a group of rheumatoid arthritis patients [24].

Corticosteroids, colchicine, and high doses of nonsteroidal anti-inflammatory drugs have all been used to treat TRAPS with varied success. Unlike FMF, TRAPS patients generally respond poorly to colchicine [15,25]. TRAPS symptoms can be relieved with high doses of prednisolone (>20 mg), although efficacy fades with time [13]. The greatest success in the treatment of TRAPS has been observed with etanercept (soluble TNFR2 fused to the Fc region of human IgG) in a number of small uncontrolled clinical trials [26-32]. Treatment with infliximab (anti-TNFα) in some cases, however, led to exacerbation of the disease [33,34]. Interestingly, anakinra (an IL-1 receptor antagonist) was remarkably successful in the treatment of a TRAPS patient resistant to anti-TNF therapy [35]. Since no randomised controlled trials of therapy have been carried out for this rare syndrome, there is currently no single recommended treatment.

**Mutations in TNFR1 associated with TRAPS**

The TRAPS mutations were discovered through screening programmes of patients and families who had previously presented with unexplained periodic fever. Although initial mutations were identified in patients of Irish descent (which gave rise to its original name of familial Hibernian fever), it is increasingly evident that the disease is ethnically diverse – TRAPS mutations are being discovered in Japanese, Turkish, and Arabic populations, hinting at underdiagnosis in these populations rather than prior absence [36-38].

Discovery of the mutations in TNFR1 associated with TRAPS was a seminal finding that connected this poorly understood disease with one of the canonical receptors that mediates inflammation [13]. TNFR1 is a prototypic member of the TNF receptor superfamily, characterised by a distinct pattern of disulphide bonding in the extracellular cysteine-rich domains (CRDs). TNFR1 has four CRDs in its extracellular region and an intracellular death domain that can initiate signalling leading to two opposing outcomes – inflammation and cell survival, versus cell death via apoptosis – depending on the cell type and intracellular milieu [39].

The crystal structure of TNFR1 in complex with one of its ligands, lymphotoxin-α (TNFβ), demonstrates that the majority of contact residues between ligand and receptor are located in CRD2 [40]. Recent work has demonstrated that members of the TNF receptor superfamily, including TNFR1, can self-associate in the membrane in the absence of ligand. Self-association is mediated by the so-called preligand assembly domain, which is located in the first CRD [41]. Interestingly, a structure of TNFR1 in the absence of its ligand TNF revealed a dimer of two receptors with extensive contacts between receptors in CRD1 [42].

Figure 1 illustrates the location of the TRAPS mutations, which occur predominantly in CRD1 and CRD2; there are no known TRAPS mutations in the transmembrane or intracellular domain of TNFR1. A definitive list of all the TRAPS mutations can be found on the INFEVERS website [43]. Many of the mutations involve cysteine residues involved in intramolecular disulphide bonds, and others occur at residues predicted to have a pronounced effect on the overall secondary structure, such as the introduction or removal of a proline (P46L, L67P, S86P, R92P), or residues involved in hydrogen bonding between loops of the receptor (T50M, I170N) [44]. Other than single base pair changes, there is a splicing mutation that introduces an extra four amino acids [45], a single amino acid deletion [20], and an intrame interstitial deletion of nine amino acids, all in the extracellular domain [16]. Remarkably, there are no mutations encoding large truncations or deletions within the receptor, which suggests that synthesis of the mutant protein is important for disease pathogenesis.

In addition to the TNFR1 mutations identified in TRAPS that do not occur in the normal population, two rare coding
sequence variants in TNFR1 that alter single amino acids have been identified as low-penetrance risk factors for TRAPS. The R92Q amino acid substitution is carried at a low frequency (~2%) in North American and Irish populations [23,45], and the P46L mutation was found in 9% of African populations [46]. TRAPS patients with these polymorphisms have a milder syndrome, with less severe flares and almost no incidence of amyloidosis. The R92Q mutation has also been linked with other diseases associated with inflammation, such as rheumatoid arthritis and atherosclerosis [47-49]. Although the penetrance of TRAPS is high among patients with the rare TNFR1 mutations (>80%), several asymptomatic family members have been reported, suggesting that other genetic and/or environmental factors also play a role in triggering the symptoms of TRAPS.

**Molecular basis of TRAPS: new answers and new questions**

In light of our current understanding of TNF receptor signaling, this disease presents a paradox. TNFα is a prototypic proinflammatory cytokine, and exerts most of its biologic effects through TNFR1. The question therefore beckons of how these mutations, which would be predicted to lead to a nonfunctional receptor and therefore less TNFR1 signalling, can drive a proinflammatory condition. Following the earliest research, several hypotheses were proposed [13,31].

Firstly, it was suggested that the mutations might render the receptor constitutively active. Since cysteines are often affected, it seemed possible that receptors could be cross-linked at the surface through the formation of aberrant disulphide bonds between receptor pairs, resulting in constitutive TNFR1 signalling.

A second theory was that TRAPS mutations increase the affinity of the receptor for TNFα — a concept difficult to rationalise as mutations would be predicted to have a profound effect on the overall structure of TNFR1, and which is not supported by binding measurements of radiolabelled TNFα to patients’ leukocytes [31].

A third hypothesis is that TNFR1 mutations in TRAPS cause impaired cleavage of membrane-bound TNFR1, leading to reduced serum levels of soluble TNFR1. This hypothesis was
supported by initial observations that some TRAPS patient cells are resistant to phorbol-myristate acetate-induced ‘shedding’ of TNFR1 from the surface, and that serum from TRAPS patients contained reduced levels of circulating soluble TNFR1, relative to controls [13].

Functional buffering of TNF by soluble TNFR1, generated through metalloprotease-dependent cleavage of cell surface TNFR1, is a well-defined phenomenon that appears to occur constitutively, but can also occur in response to several cytokines and TNFα itself (reviewed in [50]). The resultant reservoir of free soluble TNFR1 has a homeostatic effect on signalling that is twofold: decreasing the number of sites available on the membrane for binding, and providing a pool of receptors to sequester TNFα [51]. Shed TNFR1 can function as a soluble inhibitor of TNF and forms the basis for using etanercept to treat TRAPS. In addition, it has been shown that full-length TNFR1 is released in exosome-like microvesicles, which would also be expected to contribute to functional buffering of TNFα signalling [52].

In an attempt to mimic the accepted TRAPS ‘phenotype’ of impaired receptor shedding, Xanthoulea and colleagues created a knock-in mouse that expressed a nonsheddable form of TNFR1 [53]. Mice with either heterozygous or homozygous expression of the otherwise functional receptor showed enhanced TNF signalling, with spontaneous hepatitis and increased susceptibility and severity of induced arthritis. These data indicate that either a failure to cleave TNFR1 from the cell surface or a failure to form soluble TNFR1 can predispose spontaneous inflammation – supporting an anti-inflammatory role for soluble TNFR1.

Several metalloproteases have been implicated in the cleavage of membrane-bound TNFR1 [54]. Since these enzymes target a sequence in the membrane proximal region of the receptor, it seems unlikely that mutations in domains away from this region could cause complete inhibition of cleavage. Despite this, much of the early functional work on TRAPS concentrated on this concept, which has been termed the ‘shedding hypothesis’ (Figure 2). The shedding defect in TRAPS patients’ cells, however, was subsequently found to be variable, especially between the type of cells studied, and did not occur in all cases [55]. Since shedding can also result from the secretion of exosomal vesicles, the observed defect could equally be due to a defect in this pathway, which can be triggered from within the cell [52]. Alternative explanations for the pathogenesis of inflammation in TRAPS have therefore been sought.

New concepts in the understanding of TRAPS have arisen from studies by our laboratories, and others, showing that receptor misfolding and mislocalisation is a universal feature of TNFR1 mutations in TRAPS. TNF binding studies in cells and in vitro have demonstrated that the TRAPS-associated mutant TNFR1 is unable to bind to TNF. Furthermore, we and other workers have now demonstrated that the mutant receptors fail to localise to the cell surface [56]. This defect was also observed in cells from TNFR1 ‘knock-in’ mice expressing the T50M mutation [56]. Significantly, the TRAPS-associated mutant TNFR1 was specifically retained in the ER – the retention site for misfolded proteins in the secretory pathway.

The molecular basis of intracellular retention of TRAPS-associated mutants appears to be misfolding – based on the findings that the mutant receptors fail to bind TNF, they do not make normal preligand assembly domain-dependent interactions with wild-type TNF (sTNF) receptor (sTNFR1). In this model for TNF receptor-associated periodic syndrome mutations (TRAPS), both soluble and membrane-bound TNFα are no longer sequestered by the soluble receptor, resulting in overstimulation of membrane-bound TNFR1. NO, nitric oxide; ROS, reactive oxygen species.

Figure 2

The shedding hypothesis. Mutations in TNF receptor 1 (TNFR1) were thought to impair cleavage of TNFR1 from the membrane by membrane metalloproteases, leading to depletion in the pool of soluble TNF (sTNF) receptor (sTNFR1). In this model for TNF receptor-associated periodic syndrome mutations (TRAPS), both soluble and membrane-bound TNFα are no longer sequestered by the soluble receptor, resulting in overstimulation of membrane-bound TNFR1. NO, nitric oxide; ROS, reactive oxygen species.
disease associated with this variant receptor is probably different to that of the mutations strictly associated with TRAPS. Since TRAPS is an autosomal dominant disease, with patients generally carrying one wild-type allele and one mutant allele, it was important to test the effects of coexpression of mutant and wild-type TNFR1. Despite the dramatic defects in TRAPS-associated mutant TNFR1, transfection studies found that the mutant TNFR1 did not significantly interfere with the trafficking or function of the wild-type allele [56].

These findings suggest that inflammation in TRAPS results from either haploinsufficiency of wild-type receptors or some critical function gained by the mutant TNFR1. In our opinion, haploinsufficiency of surface or soluble TNFR1 seems unlikely given the fact that no known TRAPS mutations lead to complete lack of protein expression. New studies will probably focus on the consequences of intracellularly retained mutant TNFR1 in TRAPS. It is known that TRAPS-associated mutants have functional death domains and retain the ability to activate NF-κB [56-59], but, as mentioned previously, mutant receptors do not seem to induce increased NF-κB transactivation in transfected cells.

Accumulation of mutant TNFR1 in the ER may trigger the ER stress response, which could directly or indirectly lead to inflammation. One such mechanism is the so-called ER overload response that can activate NF-κB activation [60,61]. Interestingly, CREBH, a recently identified ER sensor protein expressed in hepatocytes, can directly induce expression of acute phase proteins in response to ER stress [62]. In addition, TNFR1 itself has been implicated in the pathway leading from ER stress to activation of the JNK family of mitogen-activated protein kinases [63]. In a transfection system mutant, however, TNFR1 did not appear to directly activate ER stress responses, so this seems less likely to be at the crux of the disease mechanism [56].

A final possibility is that the retained receptors in TRAPS may alter the balance between the TNFR1-initiated signalling pathways. TNFR1 can signal via two opposing pathways that lead to either apoptosis via caspase activation or to cellular survival and inflammation via the activation of NF-κB (Figure 3). Much work has been carried out to decipher how these two opposing pathways are regulated, and it is thought that a crucial difference in the threshold of TNF activation is required for cytokine activation via NF-κB, or apoptosis induction. The accepted model for TNFR1 signalling is one in which the survival genes are the first to be activated, through the formation of a surface-bound complex. The apoptosis pathway occurs later, upon formation of a second intracellular complex in receptosomes [64,65]. Interestingly, neutrophils and dermal fibroblasts from TRAPS patients with several different mutations undergo reduced apoptosis when exposed to TNF [16,66]. Dermal fibroblasts derived from a patient with the C43S mutation showed a reduced level of apoptosis compared with normal controls, but intact production of the proinflammatory cytokines IL-6 and IL-8 when exposed to TNF. Failure of activated immune cells to undergo apoptosis in TRAPS could lead to a build up of proinflammatory cytokines. Figure 4 illustrates the possible differences in the trafficking and signalling of TNFR1 in TRAPS patient cells.

Figure 3

TNF receptor 1 signalling. TNF receptor 1 (TNFR1) ligation induces death domain-mediated recruitment of TNFR1/TRADD/TRAF2/RIP1 (complex I) at the cell surface, and this complex initiates NF-κB activation, which in turn drives production of cFLIP, an apoptotic inhibitor. Activated TNFR1 is then endocytosed and the TRADD/TRAF2/RIP1 complex dissociates from the receptor in a temporal manner. This complex then recruits FADD and caspase-8 (complex II), which activates the apoptotic machinery, provided that the levels of cFLIP are low enough to remove inhibition. Adapted from [64]. In a second model, proposed by Schneider-Brachart and colleagues [65], the apoptotic complex is internalised upon assembly in receptosomes, which fuse with golgi vesicles and signal for apoptosis from within the cell. NO, nitric oxide; ROS, reactive oxygen species.

Conclusions

Contrary to initial findings, the systemic inflammation that is characteristic of TRAPS may not be solely due to a defect in receptor shedding, but instead could stem from the consequences of misfolded and intracellularly retained TNFR1. It is, however, possible that there is not one unifying mechanism for all TRAPS mutations – the variability in symptoms among patients may be a clue towards this, and there is also a strong possibility of linked susceptibility genes.

At present, some success with anti-TNF agents is likely to steer therapeutics in this direction – but while these thera-
misfolded proteins in immune cells has not been well studied. Conversely, the effect of TNFR1 mutations outside immune cells also needs to be examined. Understanding the signaling pathways connecting protein misfolding and inflammation will be interesting in relation to this rare genetic syndrome, and will also be potentially relevant to more common inflammatory conditions.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

FCK and AAL contributed equally to this work. The authors would like to thank Anna Simon for useful comments and discussion during the preparation of this manuscript.

References

1. Drenth JP, van der Meer JW: Hereditary periodic fever. N Engl J Med 2001, 345:1748-1757.
2. Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, Kingma DW, Horwitz ME, Mansfield E, Holland SM, et al.: The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 2000, 95:3223-3231.
3. Chae JJ, Komarow HD, Cheng J, Wood G, Raben N, Liu PP, Kastner DL: Targeted disruption of pyrin, the FMR protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 2003, 11:591-604.
4. Martinon F, Burns K, Tschopp J: The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of pro-Ill-beta. Mol Cell 2002, 10:417-426.
5. Hiller S, Kohl A, Fiorito F, Herrmann T, Wider G, Tschopp J, Grutter MG, Wuthrich K: NMR structure of the apoptosis- and inflammation-related NALP1 pyrin domain. Structure 2003, 11: 1199-1205.
6. Drenth JP, van der Meer JW: The inflammasome – a linebacker of innate defense. N Engl J Med 2006, 355:730-732.
7. Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, Kastner DL: The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A 2006, 103: 9982-9987.
8. Drenth JP, Cuisset L, Grateau G, Vaessen C, van Dele–Vas J, de Jong JP, Beckmann JS, van der Meer JW, Delpech M: Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 1999, 22:178-181.
9. Houten SM, Kuis W, Duran M, de Koning TJ, van Royen-Kerkhof A, Romeijn GJ, Fresken J, Dorland L, de Barse MM, Huijbers WA, et al.: Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinemia D and periodic fever syndrome. Nat Genet 1999, 22:178-177.
10. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J: NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder. Immunity 2004, 20:319-325.
11. Mulley J, Saar K, Hewitt G, Ruschendorf F, Phillips H, Colley A, Sillence D, Reis A, Wilson M: Gene localization for an autosomal dominant familial periodic fever to 12p13. Am J Hum Genet 1998, 62:884-889.
12. McDermott MF, Ogunkolade BW, McDermott EM, Jones LC, Wan Y, Plaas KA, McCarthy J, Phelan M, Molloy MG, Powell RJ, et al.: Linkage of familial Hibernian fever to chromosome 12p13. Am J Hum Genet 1998, 62:1446-1451.
13. McDermott MF, Akessonjiev I, Galon J, McDermott EM, Ogunkolade BW, Centola M, Mansfield E, Gadina M, Kaneko L, Pettersen T, et al.: Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97: 133-144.
14. Kriegel MA, Huffmeier U, Scherb E, Scheidig C, Geiler T, Kalden JR, Reis A, Lorenz HM: Tumor necrosis factor receptor-associ-

Signalling and trafficking pathways for wild-type and mutant TNF receptor 1. In TNF receptor-associated periodic syndrome mutations (TRAPS) patient cells, mutant TNF receptor 1 (TNFR1) are retained in the endoplasmic reticulum (ER) as disulphide-linked oligomers while the wild-type (WT) receptors traffic to the cell surface, leaving TNFα-induced NF-κB activation intact. ER-retained oligomers may independently activate novel signalling pathways leading to inflammation, may modify ER stress-induced responses, or may block TNFα-induced apoptosis. Mutant TNFR1 does not contribute to the antagonistic pool of soluble TNFR1 because it does not bind ligand. CRP, C-reactive protein; SAA, serum amyloid A; sTNFR1, soluble TNFR1.
ated periodic syndrome characterized by a mutation affecting the cleavage site of the receptor: implications for pathogenesis. Arthritis Rheum 2003, 48:2386-2388.

15. McDermott EM, Smillie DM, Powell RJ: Clinical spectrum of familial Hibernian fever: a 14-year follow-up study of the index case and extended family. Mayo Clin Proc 1997, 72:806-817.

16. D’Osualdo A, Ferlito F, Prigione I, Obici L, Meini A, Zulian F, Pon-tillo A, Corona F, Barcellona R, Di Mauro M, et al.: Neutrophil activation and autoantibody response to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 2004, 56:998-1008.

17. Saulsbury FT, Wispelwey B: Tumor necrosis factor receptor-associated periodic syndrome in a young adult who had features of familial Mediterranean fever. J Pediatr 2005, 146:283-285.

18. Totil A, Zhao J, Bielke B, Reiser A, Volesky P, Niznik HB, Antin C, Kornfeld S, Schonfeld HJ: X-linked dominant periodic syndrome due to TNFRSF1A mutations disulfide bond resistance to tumor necrosis factor. Hum Genet 1997, 99:66-73.

19. Hull KM, Wong K, Wood GM, Chu WS, Kastner DL: Monocytic fasciitis: a newly recognized clinical feature of tumor necrosis factor receptor dysfunction. Arthritis Rheum 2002, 46:2189-2194.

20. Arganega E, Hammond L, Hawkins PN, Aledea A, McKee SA, van Amstel HK, Mischung C, Kusuhara S, Saulsbury FT, Lachmann HJ, et al.: Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 2002, 46:2632-2643.

21. Dodi C, Guisez Y, Delpech M, grateau G: TNFRSF1A-associated periodic syndrome (TRAPS), Muckle–Wells syndrome (MWS) and renal amyloidosis. J Nephrol 2003, 16:435-437.

22. Rudolfsky G, Jr, Hoffmann F, Muller K, Filser M, Lohse P, Beimer J, Schwenger V: A nephrotic patient with tumour necrosis factor receptor-associated periodic syndrome, IgA nephropathy and CNS involvement. Nephrol Dial Transplant 2006, 21:1109-1112.

23. Hassle J, Illum L, Jensen TF, Vestergaard P, Madsen O, Gerdes H, Thomsen F, Brix K, Kjaer SK: TNF receptor 1 gene polymorphisms are associated with myocarditis and sacroiliitis: a family-based association study. Eur J Hum Genet 2002, 10:230-237.

24. Nowlan ML, Dwee E, Bulsara H, Esposito N, Robins RA, Tighe PJ, Powell RJ, Todd I: Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Arthritis Rheum 2003, 48:2632-2643.

25. Aganna E, Zeharia A, Hitman GA, Basel-Vanagaite L, Allotey RA, Booth DR, Hawkins PN, Thacker C, Syndinme-Court D, McDermott MP: An Israeli Arab patient with a de novo TNFRSF1A mutation causing tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2002, 46:245-249.

26. Muddpiti JR, Tschopp J, Siegel RM: Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signaling transduction. Immunity 2004, 21:481-485.

27. Cahill DW, D’Arcy A, Janwes J, Gentz R, Schoenfeld HJ, Broger C, Loetscher H, Lesslauer W: Crystal structure of the soluble human 55 kD TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993, 73:431-445.

28. Galacteros F, Segbena Y, Prehu C, Tchernitchko D, Chimiqngi M, Tchernitchko D, Galacteros F, Prehu C, Segbena Y, Tchernitchko D, Galacteros F, Prehu C, Segbena Y: Familial Hibernian fever: a 14-year follow-up study of the index case and extended family. Arthritis Rheum 2006, 54:1031-1037.

29. Offer M, Lachmann HJ, Bybee A, Rowczenio DM, Goodman HJ, Arveiler D, Ducimetiere P, et al.: Systemic Inflammatory Disorders; Bethesda, MD; 2005.

30. Aganna E, Bodar EJ, van der Meer JW, Arveiler D, Ducimetiere P, Keitzer R, Querfeld U, Haffner D: Familial Hibernian fever. Arthritis Rheum 2000, 43:1012-1017.

31. Galanter J, Aksentijevich I, McDermott MF, O’Shea JI, Kastner DL: TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 2000, 12:479-486.

32. Arostegui JI, Solis P, Aledea A, Cantero T, Rius J, Bahillo P, Plaza S, Vives J, Gomez S, Yague J: Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associ-ated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response. Eur J Pediatr 2005, 164:13-16.

33. Offer M, Lachmann HJ, Bybee A, Rowczenio DM, Goodman HJ, Hawkins PN: Phenotype and response to treatment of 22 patients with autoinflammatory disease associated with mutations in TNFRSF1A. In FMF and beyond. Fourth International Conference on Systemic Inflammatory Disorders; Bethesda, MD, 2005.

34. Offer M, Bodar EJ, van der Meer JW, Arveiler D, Ducimetiere P, Keitzer R, Querfeld U, Haffner D: Multiple co-occurrences of TNF receptor-associated periodic syndrome. In FMF and beyond. Fourth International Conference on Systemic Inflammatory Disorders; Bethesda, MD, 2005.

35. Aganna E, Bodar EJ, van der Meer JW, Arveiler D, Ducimetiere P, Keitzer R, Querfeld U, Haffner D: Familial Hibernian fever. Arthritis Rheum 2000, 43:1012-1017.

36. Offer M, Lachmann HJ, Bybee A, Rowczenio DM, Goodman HJ, Arveiler D, Ducimetiere P, et al.: Systemic Inflammatory Disorders; Bethesda, MD; 2005.

37. Dinc A, Erdem H, Rowczenio D, Simsek I, Pay S, Bahce M, Lach-mann H: Autosomal dominant periodic fever with AA amyli-odosis: tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Turkish family. J Nephrol 2005, 18:626-629.

38. Arganega E, Zeharia A, Hitman GA, Basel-Vanagaite L, Alotey RA, Booth DR, Hawkins PN, Thacker C, Syndinme-Court D, McDermott MP: A Turkish patient with a novel mutation in TNFRSF1A, Muckle–Wells syndrome and renal amyloidosis. Nephrol Dial Transplant 2006, 21:314-320.

39. Offer M, Lachmann HJ, Bybee A, Rowczenio DM, Goodman HJ, Arveiler D, Ducimetiere P, et al.: Systemic Inflammatory Disorders; Bethesda, MD; 2005.

40. Banner DW, D’Arcy A, Janwes J, Gentz R, Schoenfeld HJ, Broger C, Loetscher H, Lesslauer W: Crystal structure of the soluble human 55 kD TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993, 73:431-445.

41. Galacteros F, Segbena Y, Tchernitchko D, Galacteros F, Prehu C, Segbena Y, Tchernitchko D, Galacteros F, Prehu C, Segbena Y: Familial Hibernian fever. Arthritis Rheum 2000, 43:1012-1017.

42. Offer M, Lachmann HJ, Bybee A, Rowczenio DM, Goodman HJ, Arveiler D, Ducimetiere P, et al.: Systemic Inflammatory Disorders; Bethesda, MD; 2005.

43. Offer M, Lachmann HJ, Bybee A, Rowczenio DM, Goodman HJ, Arveiler D, Ducimetiere P, et al.: Systemic Inflammatory Disorders; Bethesda, MD; 2005.

44. Galanter J, Aksentijevich I, McDermott MF, O’Shea JI, Kastner DL: TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 2000, 12:479-486.

45. Arostegui JI, Solis P, Aledea A, Cantero T, Rius J, Bahillo P, Plaza S, Vives J, Gomez S, Yague J: Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associ-ated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response. Eur J Pediatr 2005, 164:13-16.
patients with Behcet's disease. *Arthritis Rheum* 2005, 52:608-611.

50. Aderka D: The potential biological and clinical significance of the soluble tumor necrosis factor receptors. *Cytokine Growth Factor Rev* 1996, 7:231-240.

51. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. *Proc Natl Acad Sci U S A* 1992, 89:4845-4849.

52. Hawari FI, Rouhani FN, Cui X, Yu ZX, Buckley C, Kaler M, Levine SJ: Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. *Proc Natl Acad Sci U S A* 2004, 101:1297-1302.

53. Xanthoulea S, Pasparakis M, Kroustani S, Brakebusch C, Wallach D, Bauer J, Lassmann H, Kollia G: Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. *J Exp Med* 2004, 200:357-376.

54. Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, Shows D, Peschon JJ, Black RA: Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. *J Biol Chem* 2000, 275:14608-14614.

55. Huggins ML, Radford PM, McIntosh RS, Bainbridge SE, Dickinson P, Draper-Morgan KA, Tighe PJ, Powell RJ, Todd I: Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: differences between cell types. *Arthritis Rheum* 2004, 50:2651-2659.

56. Lobito AA, Kimberley FC, Muppidi JR, Komarov H, Jackson AJ, Hull KM, Kastner DL, Screenon GR, Siegel RM: Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in the TNFR1 associated periodic fever syndrome (TRAPS). *Blood* 2006, 109:1320-1327.

57. Todd I, Radford PM, Draper-Morgan KA, McIntosh R, Bainbridge S, Dickinson P, Jamhawi I, Sanaaridis M, Huggins ML, Tighe PJ, et al.: Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndromes retain signalling functions but show abnormal behaviour. *Immunology* 2004, 113:65-79.

58. Siebert S, Fielding CA, Williams BD, Brennan P: Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF-kappaB activation due to decreased surface expression. *FEBS Lett* 2005, 579:5193-5198.

59. Youasf N, Gould DJ, Aganna E, Hammond L, Mirakian RM, Turner MD, Hitman GA, McDermott MF, Chernajovsky Y: Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-kappaB activation. *Arthritis Rheum* 2005, 52:2906-2916.

60. Pahl HL, Baeuerle PA: The ER-overload response: activation of NF-kappaB. *Trends Biochem Sci* 1997, 22:53-67.

61. Schroder M, Kaufman RJ: The mammalian unfolded protein response. *Annu Rev Biochem* 2005, 74:739-789.

62. Zhang K, Shen X, Wu J, Sakaki K, Saunders T, Rutkowski DT, Black SH, Kaufman RJ: Endoplasmic reticulum stress activates cleavage of CREB to induce a systemic inflammatory response. *Cell* 2006, 124:587-599.

63. Yang Q, Kim YS, Lin Y, Lewis J, Neckers L, Liu ZG: Tumour necrosis factor receptor 1 mediates endoplasmic reticulum stress-induced activation of the MAP kinase JNK. *EMBO Rep* 2006, 7:822-827.

64. Micheau O, Tschopp J: Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. *Cell* 2003, 114:181-190.

65. Schneider-Brachert W, Tschopp J: Compartmentalization of NF-kappaB signaling: internalized TNF receptosomes as death signaling vesicles. *Immunity* 2004, 21:415-428.

66. Siebert S, Amos N, Fielding CA, Wang EC, Akseintievich I, Williams BD, Brennan P: Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. *Arthritis Rheum* 2005, 52:1287-1292.